614 McKinley Place NE
United States - Map
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic products worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal antibodies in goats, sheep, and rabbits, as well as monoclonal antibodies; microtiter-plate based kits under the Quantikine trade name, immunoassays based on encoded bead technology, and immunoassays based on planar spotted surfaces for researchers to quantify the level of a specific protein in biological fluids; and erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers flow cytometry products, such as fluorochrome labeled antibodies and kits for use in determining the immuno-phenotypic properties of cells from various tissues; and natural or synthetic chemical compounds for use by investigators as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides a range of hematology controls and calibrators for impedance and laser type cell counters; and hematology control products for use as proficiency testing tools by laboratory certifying authorities. The Protein Platforms segment develops, manufactures, and sells tools comprising Simple Western platform, an assay for protein analysis and identification; SimplePlex platform, an assay used in research and clinical diagnostics; and Biologics Instrumentation to interrogate protein purity and identify contaminants during the development and production of biologics. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
|Bio-Techne Corp.’s ISS Governance QuickScore as of Feb 1, 2016 is 1. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 1; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Charles R. Kummeth ,
Chief Exec. Officer, Pres and Director
|Mr. James T. Hippel ,
Chief Financial Officer and VP of Fin.
|Ms. Brenda S. Furlow J.D.,
Sr. VP, Gen. Counsel and Sec.
|Mr. N. David Eansor ,
Sr. VP of Biotechnology
|Mr. Robert M. Gavin ,
Sr. VP of Protein Platforms Division
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|